Aquestive Therapeutics, Inc. ((AQST)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aquestive Therapeutics’ latest earnings call struck a tone of cautious optimism, as management laid out a clearer regulatory and launch roadmap while acknowledging deeper losses and heavier cash burn. Executives pointed to a strengthened balance sheet and detailed plans to overcome the FDA’s Complete Response Letter, but investors were reminded that approval, market adoption and funding needs still carry meaningful execution risk.
Regulatory roadmap for ANNAFILM resubmission
Aquestive underscored that the regulatory path for ANNAFILM is now better defined, with a Type A meeting request already filed and feedback expected within about 30 days. Management plans to resubmit the NDA in the third quarter of 2026, supported by contracted CROs and finalized protocols for the required human‑factors validation and supportive PK studies.
Operational readiness and packaging refinements
Operationally, the company has moved quickly to address the FDA’s concerns, including redesigned packaging that makes pouches easier to open without affecting product stability. CROs are in place for the upcoming human‑factors and PK work, and management has optional clinical trial designs ready so they can align rapidly with any additional FDA guidance.
Expanded clinical and medical affairs bench
The leadership team highlighted the hiring of Dr. Matt Greenhawk as Chief Medical Officer and Dr. Matthew Davis as Chief Development Officer to deepen clinical oversight. Medical affairs staffing is set to more than double, aimed at boosting conference presence, publications and physician education as ANNAFILM approaches potential launch.
Scaling commercial launch plans to 75 reps
On the commercial side, Aquestive now expects to deploy roughly 75 sales representatives at launch, up from prior plans for about 50. The larger footprint is intended to widen physician coverage and reduce “white space” in territories, with contingent hiring planned so the field force can be mobilized quickly once approval is secured.
Financing strength and liquidity options
From a capital standpoint, the company ended 2025 with $121.2 million in cash after completing an $85 million equity raise during the year. RTW extended its revenue‑share agreement through mid‑2027, added a $5 million investment and left a $75 million revenue‑interest facility available post‑approval, giving Aquestive multiple levers to fund commercialization.
Mixed revenue picture with Q4 uptick
Revenue trends showed a modest improvement in the latest quarter but a softer full‑year backdrop when one‑time items are included. Fourth‑quarter revenue rose about 10% year over year to $13.0 million, driven mainly by manufacturer and supply revenue, while full‑year 2025 revenue of $44.5 million was down roughly 3% excluding a prior‑year deferred revenue benefit.
Lower R&D spend and pipeline advances
R&D expenses declined meaningfully, falling to $3.2 million in the fourth quarter from $4.9 million a year earlier and to $17.2 million for 2025 from $20.3 million in 2024. Despite tighter spending, the company opened an IND for its AQST‑108 program in December, completed initial safety dosing and expects topline clinical data in the near term.
Epinephrine market dynamics and demand signals
Management painted a constructive picture of the epinephrine market, which grew just over 9% in 2025 with auto‑injector prescriptions up about 5%. While more than 90% of prescriptions still sit with auto‑injectors, allergists are reportedly expressing strong interest in an oral film alternative, supported by positive feedback gathered at recent professional meetings.
Legal overhangs diminish after settlement
The company also moved to clean up its legal backdrop by settling a nine‑year defamation case, removing what management called a long‑standing distraction. They noted this is the fourth legal matter to be withdrawn, dismissed or settled in the last four years, potentially reducing future volatility in expenses and focus.
Surging SG&A driven by legal and launch prep
The flip side of Aquestive’s ramp‑up is a sharp increase in SG&A, which climbed to $79.8 million in 2025 from $50.2 million in 2024. One‑time legal fees contributed about $14.3 million for the full year, including $13.6 million in the fourth quarter alone, but prelaunch commercial build‑out also drove underlying SG&A higher.
Deepening losses and negative adjusted EBITDA
Loss metrics deteriorated significantly as spending outpaced revenue growth, even after stripping out legal costs. Full‑year 2025 net loss excluding one‑time legal expenses widened to $70.6 million from $44.1 million, while non‑GAAP adjusted EBITDA loss (also excluding legal) nearly doubled to $49.7 million, underscoring heavier operating drag ahead of launch.
Top‑line pressure including deferred revenue impact
When including the prior‑year deferred revenue recognition, the company’s top line showed a more pronounced decline. Total revenue fell to $44.5 million in 2025 from $57.6 million in 2024, a drop of about 22.7%, and even on a normalized basis revenues slipped around 3%, highlighting the importance of future product launches to reaccelerate growth.
High cash burn and runway considerations
Guidance implies a substantial cash burn over the next year, with year‑end 2026 cash expected around $70 million versus $121.2 million at the end of 2025. That projected drawdown, which excludes any incremental RTW proceeds or out‑licensing deals, suggests Aquestive may eventually need additional capital if ANNAFILM approval or partnering timelines slip.
Regulatory overhang from CRL requirements
At the core of the story is the prior Complete Response Letter for ANNAFILM, which mandates a human‑factors validation study and a supportive PK study. Management views the steps as manageable, but the added work injects timing and execution risk into the approval and launch schedule that investors must factor into valuation.
Competitive landscape and adoption challenges
Competitive dynamics also weigh on the opportunity, as entrenched auto‑injector devices still capture the vast majority of prescriptions and rival players are spending heavily on marketing. Even with evident interest from allergists, converting patients and physicians to a novel oral film format may take time and sustained commercial investment.
Prioritization trade‑offs across Libervant and AQST‑108
Resource constraints are forcing strategic choices, with management signaling that Libervant will likely be out‑licensed in the U.S. rather than launched in‑house. Development of AQST‑108 will be deprioritized while the company focuses capital and attention on ANNAFILM resubmission and approval, potentially slowing the pace of follow‑on pipeline value creation.
Guidance and outlook for 2026 and beyond
Looking ahead, Aquestive reiterated plans to resubmit ANNAFILM’s NDA in the third quarter of 2026, conduct the required FDA‑aligned studies and launch commercially within roughly eight weeks of potential approval with about 75 sales reps, while also targeting regulatory filings in Europe and Canada. For 2026, management guided to $46–50 million in revenue, a non‑GAAP adjusted EBITDA loss of $30–35 million and year‑end cash of roughly $70 million, supported by an extended RTW facility that leaves $75 million available post‑approval.
The call sketched a company leaning hard into ANNAFILM as its value driver, balancing regulatory clarity and growing physician interest against steeper losses and funding needs. For investors, the story now hinges on successful execution of the FDA‑mandated studies, timely resubmission and the ability to carve share from an entrenched auto‑injector market without overextending the balance sheet.